Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.…
Biofrontera: 3 Key Takeaways for Long-Term Investors
Biofrontera (NASDAQ: BFRI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 84 employees.
The shares were at 0.5300 USD on 20 November 2026, down 50.9% over 52 weeks. Its 52-week range is 0.5300 USD to 1.660 USD, and it trades at the bottom of that range.
Its market capitalisation is 9.51M USD.
Biofrontera reports return on equity of -100.5%, an operating margin of -12.6% and revenue up 29.8% year over year.
Its debt exceeds its cash by 4.30M USD, a debt-to-equity ratio of 0.59. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.